Abstract In late November 2021, the World Health Organization declared the SARS-CoV-2 lineage B.1.1.529 the fifth variant of concern, Omicron. This variant has acquired 15 mutations in the receptor binding domain of the spike protein, raising concerns that Omicron could evade naturally acquired and vaccine-derived immunity. We utilized an authentic virus, multicycle neutralisation assay to demonstrate that sera collected one, three and six months post-two doses of Pfizer-BioNTech BNT162b2 has a limited ability to neutralise SARS-CoV-2. However, four weeks after a third dose, neutralising antibody titres are boosted. Despite this increase, neutralising antibody titres are reduced four-fold for Omicron compared to lineage A.2.2 SARS-CoV-2.

Improved neutralisation of the SARS-CoV-2 Omicron variant after Pfizer-BioNTech (BNT162b2) COVID-19 vaccine boosting with a third dose

Scan to connect with one of our mobile apps

Coinbase Wallet app

Coinbase app

Or try the Coinbase Wallet browser extension